Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0001175,
umls-concept:C0001857,
umls-concept:C0019682,
umls-concept:C0019699,
umls-concept:C0035647,
umls-concept:C0205216,
umls-concept:C0332281,
umls-concept:C0332307,
umls-concept:C0449258,
umls-concept:C0449435,
umls-concept:C0871261,
umls-concept:C1511636,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
pubmed:issue |
8
|
pubmed:dateCreated |
1996-1-11
|
pubmed:abstractText |
The duration of human immunodeficiency virus (HIV-1) infection prior to the development of AIDS is variable, and for most patients the exact time of infection is not known. A group of 38 HIV-1-infected subjects was tested while asymptomatic for comparative cytotoxic lymphocyte responses to the Gag and envelope antigens of HIV-1. Twenty of the 38 patients had no detectable primary cytotoxic T lymphocyte (CTL) response to Gag, and this was associated with a relative risk of 1.89 for progression to ARC or AIDS during the subsequent 3 to 40 months of observation when compared with patients who had Gag-specific CTL activity at the beginning of the observation period. In contrast, no significant association was observed between envelope-specific cytotoxic activity and disease progression. Other patient characteristics, including CD4+ T lymphocyte counts and antibody levels to the p24gag protein, measured at the start of observation, did not correlate with disease progression during the observation period. This suggests that the anti-Gag CTL response may be protective during HIV-1 infection.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0889-2229
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
903-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7492437-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:7492437-CD4-Positive T-Lymphocytes,
pubmed-meshheading:7492437-Cytotoxicity, Immunologic,
pubmed-meshheading:7492437-Gene Products, gag,
pubmed-meshheading:7492437-HIV Infections,
pubmed-meshheading:7492437-HIV-1,
pubmed-meshheading:7492437-Humans,
pubmed-meshheading:7492437-Prognosis,
pubmed-meshheading:7492437-Risk Factors
|
pubmed:year |
1995
|
pubmed:articleTitle |
Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS.
|
pubmed:affiliation |
URA CNRS 1157 Département des Rétrovirus, Institut Pasteur, Paris, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|